Treatment is incredibly important for metabolic dysfunction-associated steatohepatitis (MASH). Without treatment, MASH may progress to cirrhosis, or scarring of the liver.
In this video, learn the medications and lifestyle changes that help treat MASH, according to Alyson Fox, MD, MSCE, Transplant Hepatologist at Columbia University’s Irving Medical Center.
Alyson Fox, MD, is the Medical Director of the Adult Liver Transplant Program at Columbia University’s Irving Medical Center. She specializes in a variety of liver conditions, including viral hepatitis, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, and liver cancer.
References
American Academy of Family Physicians. (2024). Nonalcoholic fatty liver disease (metabolic dysfunction-associated steatotic liver disease).
Likhitsup, A. (2024). Metabolic dysfunction-associated steatotic liver disease (MASLD). American College of Gastroenterology.
Madrigal Pharmaceuticals, Inc. (2024). REZDIFFRA (resmetirom) tablets, for oral use [package insert].
MedlinePlus. (2024). Resmetirom.
Novo Nordisk Inc. (2023). WEGOVY (semaglutide) injection, for subcutaneous use [package insert].
National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Definition & facts of NAFLD & NASH.
Sharma, B., et al. (2023). Nonalcoholic steatohepatitis. StatPearls.
U.S. Food & Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease.
U.S. Food & Drug Administration. (2025). FDA approves treatment for serious liver disease known as ‘MASH’.
Why trust our experts?
